EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...
The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.
Company to present 40-week topline results from the Phase 2 study of migaldendranib (MGB), a first-in-class subcutaneous nanomedicine, being ...
The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback